Gopalan N, et al. - Experts probed into the efficacy and safety of daily, part-daily, and intermittent antituberculosis therapy regimens in the treatment of HIV-associated pulmonary tuberculosis (TB) in adults infected with HIV with newly diagnosed, culture-positive, pulmonary TB between September 14, 2009, and January 18, 2016. Favourable responses were experienced by 91% (89 of 98), 80% (77 of 96), and 77% (75 of 98) of the cases in the daily, part-daily, and intermittent regimens, respectively. The inference drawn was that a daily anti-TB regimen was superior to a thrice-weekly regimen with regard to the efficacy and emergence of rifampicin resistance among HIV-positive patients with pulmonary TB receiving antiretroviral therapy.